wildtype CD27 CAR-T

Wildtype CD27 CAR-T is an experimental chimeric antigen receptor (CAR) T-cell therapy that utilizes the extracellular domain of the natural ligand CD27 to target CD70-expressing tumor cells. CD70 is a member of the tumor necrosis factor (TNF) superfamily and is highly expressed in various malignancies, including acute myeloid leukemia (AML) and renal cell carcinoma, while maintaining limited expression on healthy tissues. In this construct, the native CD27 sequence serves as the antigen-binding domain, providing a "natural ligand" approach that often demonstrates superior performance compared to traditional scFv-based binders. In preclinical studies conducted by researchers at UCSF and UC Berkeley, the wildtype CD27 CAR-T demonstrated potent anti-tumor activity and antigen-specific cytotoxicity, although it is currently being used as a baseline to evaluate next-generation variants optimized through machine learning for enhanced affinity and persistence.

Other names

wildtype CD27-based CAR-TCD27 natural ligand CAR-TCD-27 natural ligand CAR-TCD 27 natural ligand CAR-T